Loading

Commentary Open Access
Volume 3 | Issue 3 | DOI: https://doi.org/10.33696/diabetes.3.044

Commentary on Once-Weekly Semaglutide in Adults with Overweight or Obesity

  • 1Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Vanderbilt University School of Medicine, Nashville,TN, USA
  • 2Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA
  • 3Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA
+ Affiliations - Affiliations

Corresponding Author

Gitanjali Srivastava, gitanjali.srivastava@vumc.org

Received Date: August 19, 2021

Accepted Date: August 24, 2021

Keywords

GLP-1R agonist, Semaglutide, Overweight, Obesity, Weight loss, Diabetes, Anti-obesity medication

Author Information X